The Neuromyelitis Optica (NMO) market centers on a spectrum of targeted immunotherapies designed to prevent debilitating relapses, preserve neurological function and improve quality of life in patients with this rare autoimmune disorder. Key products include monoclonal antibodies such as eculizumab, satralizumab and inebilizumab, which inhibit complement activation or block interleukin-6 signaling pathways. These biologics offer Neuromyelitis Optica Market advantages over broad-spectrum immunosuppressants by delivering precise action, a lower risk of systemic toxicity, and durable control of disease activity. Complementary offerings such as aquaporin-4 antibody assays, plasmapheresis kits and supportive neurological care devices further enhance diagnostic accuracy and treatment monitoring. An increasing number of hospitals and specialty clinics are integrating these therapies into standard practice, driven by growing physician awareness and patient advocacy for better treatment options. Additionally, manufacturers are investing in scalable production and streamlined supply chains to reduce costs and broaden access.

According to CoherentMI,The Neuromyelitis Optica Market is estimated to be valued at USD 1.14 Billion in 2025 and is expected to reach USD 2.29 Billion by 2032, growing at a compound annual growth rate (CAGR) of 10.5% from 2025 to 2032.

Get More Insight On: Neuromyelitis Optica Market

Get this Report in Japanese Language: 視神経脊髄炎市場

Get this Report in Korean Language: 시신경척수염시장